“Scientists rethink Alzheimer’s, diversifying the drug search,” by Lauran Neergaard, Associated Press

“For years researchers have been guided by one leading theory — that getting rid of a buildup of a sticky protein called amyloid would ease the mind-robbing disease. Yet drug after drug has failed. They might clear out the gunk, but they’re not stopping Alzheimer’s inevitable worsening. The new mantra: diversify. With more money — the government had a record $2.4 billion to spend on Alzheimer’s research this year — the focus has shifted to exploring multiple novel ways of attacking a disease now considered too complex for a one-size-fits-all solution. On the list, researchers are targeting the brain’s specialized immune system, fighting inflammation, even asking if simmering infections play a role.”

LTC Comment (from Stephen A. Moses, President, Center for Long-Term Care Reform):

When nothing works, examine your premises. Then try something, many things, new.